Enanta Pharmaceuticals Highlights Virology and Immunology Advances at J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals Showcases Commitment to Virology and Immunology at J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology firm based in Watertown, Massachusetts, is poised to highlight its innovative approach to drug discovery at the upcoming 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2024. The company's President and CEO, Jay R. Luly, Ph.D., will present at 8:15 a.m. PT in San Francisco, California. This annual conference serves as a significant venue for biopharmaceutical companies to share their advancements and strategic visions with a broad audience of investors and industry stakeholders. Enanta's participation underscores its commitment to addressing pressing health challenges through its focused research in virology and immunology.

At the core of Enanta's operations is a strong, chemistry-driven approach that facilitates the discovery of small molecule drugs. Currently, the company is directing its clinical efforts towards treating respiratory syncytial virus (RSV), a leading cause of respiratory illness in infants and young children. This focus reflects Enanta's strategy to tackle major viral infections that significantly impact public health. Additionally, the company is developing therapies for inflammatory diseases through its immunology pipeline, which aims to inhibit key mechanisms like KIT and STAT6. These efforts position Enanta as a frontrunner in creating effective treatments for diseases that currently lack adequate solutions.

Enanta's legacy includes the discovery of glecaprevir, a protease inhibitor that is a cornerstone of treatment regimens for chronic hepatitis C virus (HCV) infections, marketed by AbbVie under the names MAVYRET® in the U.S. and MAVIRET® internationally. The royalties from HCV products developed in collaboration with AbbVie are vital for supporting Enanta’s ongoing research and operational activities. By leveraging its success in HCV, the company continues to invest in innovative solutions within the realms of virology and immunology, reinforcing its standing as a significant player in the biotechnology landscape.

Enanta encourages those interested in its advancements to access a live webcast of the J.P. Morgan presentation via its website, where a replay will also be available for at least 30 days. This event not only highlights Enanta’s ongoing commitment to developing novel therapies but also serves to engage a wider audience in its mission to combat serious health issues through innovative drug discovery. For more information about its programs and initiatives, stakeholders can visit Enanta Pharmaceuticals' website at www.enanta.com.